BCL-6 expression in mesenchymal tumours: an immunohistochemical and fluorescence in situ hybridisation study
The BCL-6 proto-oncogene encodes a transcriptional repressor protein. Among normal tissues, BCL-6 expression is confined to germinal center B-cells and a subpopulation of T-helper cells. Little is known about BCL-6 expression in mesenchymal tissues. We examined a series of solitary fibrous tumor (SF...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical pathology 2011-10, Vol.64 (10), p.866-869 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 869 |
|---|---|
| container_issue | 10 |
| container_start_page | 866 |
| container_title | Journal of clinical pathology |
| container_volume | 64 |
| creator | Walters, Matthew P McPhail, Ellen D Law, Mark E Folpe, Andrew L |
| description | The BCL-6 proto-oncogene encodes a transcriptional repressor protein. Among normal tissues, BCL-6 expression is confined to germinal center B-cells and a subpopulation of T-helper cells. Little is known about BCL-6 expression in mesenchymal tissues. We examined a series of solitary fibrous tumor (SFT) and other mesenchymal tumors for BCL-6 expression. Immunohistochemistry for BCL-6 was performed on 64 mesenchymal tumors [26 SFT (19 benign/uncertain, 7 malignant), 6 synovial sarcomas (SS), 5 gastrointestinal stromal tumors (GIST), 5 malignant peripheral nerve sheath tumors (MPNST), 5 leiomyosarcomas (LMS), 9 leiomyomas (LM) 4 desmoid tumors (DT), 4 perineuriomas (PN)]. Nuclear immunoreactivity was considered positive. Six BCL-6 positive SFT were also tested for BCL-6 gene rearrangement/amplification by FISH. Nuclear expression of BCL-6 was seen in 13/26 SFT, 5/5 LMS, 1/9 LM, 5/6 SS, 1/5 GIST, 1/5 MPNST, 1/4 PN, and 0/5 DT. BCL-6 expression was significantly more frequent in malignant (6/7) as compared with benign/uncertain SFT (6/19) (p=0.02) and in LMS (5/5) as compared with LM (1/9) (p=0.003). FISH for BCL-6 rearrangement/amplification was negative in all tested cases. We have observed BCL-6 expression in 50% or more of SFT, SS, and LMS, and in a lesser percentage of LM, GIST, MPNST and PN. Significantly more frequent expression of BCL-6 in malignant compared with benign/uncertain SFT and in LMS compared with LM suggests abnormalities in the BCL-6 signaling pathway may contribute to malignant transformation in at least some mesenchymal tumors. It is unlikely that BCL-6 expression in mesenchymal tumors is due to BCL-6 gene amplification or rearrangement. amplification or rearrangement. |
| doi_str_mv | 10.1136/jclinpath-2011-200185 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_894816636</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>894816636</sourcerecordid><originalsourceid>FETCH-LOGICAL-b445t-ffadf0d6e2c7f77a1495cc4967756c0d84ad79181e753684d6df30d7a01c1be13</originalsourceid><addsrcrecordid>eNqNkUtv1DAUhS1ERaeFnwCKhBCrUN_4lbCDEW2RRkXiubQcPxQPcTLYidT59_UowyCx6sZenO9cnXsPQi8BvwMg_Gqrez_s1NSVFQbID4aaPUEroKIqKVD-FK0wrqBsBOXn6CKlbUaIAPIMnVcgKoZptUL9x_Wm5IW930Wbkh-Hwg9FsMkOutsH1RfTHMY5pveFylII8zB2Pk2j7mzwOutqMIXr5zHbdTbZgz_5aS66fRu98UlNh6lpms3-OTpzqk_2xfG_RD-uP31f35abLzef1x82ZUspm0rnlHHYcFtp4YRQQBumNW24EIxrbGqqjGigBisY4TU13DiCjVAYNLQWyCV6u8zdxfHPbNMkg8_p-l4NdpyTrBtaA-eEZ_L1f-Q2bzvkcBJEDZgIDCJTbKF0HFOK1sld9EHFvQQsD23IUxvy0IZc2si-V8fpcxusObn-nj8Db46ASvmYLqpB-_SPo4xjqEjmyoXLp7f3J13F35ILIpi8-7mWnP76dn1z-1U2mccL34btI7M-AOqPtN4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1781037017</pqid></control><display><type>article</type><title>BCL-6 expression in mesenchymal tumours: an immunohistochemical and fluorescence in situ hybridisation study</title><source>MEDLINE</source><source>BMJ Journals - NESLi2</source><source>PubMed Central</source><creator>Walters, Matthew P ; McPhail, Ellen D ; Law, Mark E ; Folpe, Andrew L</creator><creatorcontrib>Walters, Matthew P ; McPhail, Ellen D ; Law, Mark E ; Folpe, Andrew L</creatorcontrib><description>The BCL-6 proto-oncogene encodes a transcriptional repressor protein. Among normal tissues, BCL-6 expression is confined to germinal center B-cells and a subpopulation of T-helper cells. Little is known about BCL-6 expression in mesenchymal tissues. We examined a series of solitary fibrous tumor (SFT) and other mesenchymal tumors for BCL-6 expression. Immunohistochemistry for BCL-6 was performed on 64 mesenchymal tumors [26 SFT (19 benign/uncertain, 7 malignant), 6 synovial sarcomas (SS), 5 gastrointestinal stromal tumors (GIST), 5 malignant peripheral nerve sheath tumors (MPNST), 5 leiomyosarcomas (LMS), 9 leiomyomas (LM) 4 desmoid tumors (DT), 4 perineuriomas (PN)]. Nuclear immunoreactivity was considered positive. Six BCL-6 positive SFT were also tested for BCL-6 gene rearrangement/amplification by FISH. Nuclear expression of BCL-6 was seen in 13/26 SFT, 5/5 LMS, 1/9 LM, 5/6 SS, 1/5 GIST, 1/5 MPNST, 1/4 PN, and 0/5 DT. BCL-6 expression was significantly more frequent in malignant (6/7) as compared with benign/uncertain SFT (6/19) (p=0.02) and in LMS (5/5) as compared with LM (1/9) (p=0.003). FISH for BCL-6 rearrangement/amplification was negative in all tested cases. We have observed BCL-6 expression in 50% or more of SFT, SS, and LMS, and in a lesser percentage of LM, GIST, MPNST and PN. Significantly more frequent expression of BCL-6 in malignant compared with benign/uncertain SFT and in LMS compared with LM suggests abnormalities in the BCL-6 signaling pathway may contribute to malignant transformation in at least some mesenchymal tumors. It is unlikely that BCL-6 expression in mesenchymal tumors is due to BCL-6 gene amplification or rearrangement. amplification or rearrangement.</description><identifier>ISSN: 0021-9746</identifier><identifier>EISSN: 1472-4146</identifier><identifier>DOI: 10.1136/jclinpath-2011-200185</identifier><identifier>PMID: 21725042</identifier><identifier>CODEN: JCPAAK</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd and Association of Clinical Pathologists</publisher><subject>aeromonas ; bcl-6 ; Biological and medical sciences ; Biomarkers, Tumor - analysis ; Biomarkers, Tumor - genetics ; Cell Transformation, Neoplastic - chemistry ; Cell Transformation, Neoplastic - genetics ; cytogenetics ; DNA-Binding Proteins - analysis ; DNA-Binding Proteins - genetics ; Gene Amplification ; Gene Rearrangement ; haematopathology ; Humans ; Immunohistochemistry ; immunophenotyping of leukaemias/lymphomas ; in situ hybridisation ; In Situ Hybridization, Fluorescence ; Investigative techniques, diagnostic techniques (general aspects) ; lymphoma ; malt-lymphoma ; Medical sciences ; Mesoderm - chemistry ; Mesoderm - pathology ; Minnesota ; molecular genetics ; neoplasms ; Neoplasms, Connective Tissue - chemistry ; Neoplasms, Connective Tissue - genetics ; Neoplasms, Connective Tissue - pathology ; Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques ; Proto-Oncogene Proteins c-bcl-6 ; sarcoma ; Solitary Fibrous Tumors - chemistry ; Solitary Fibrous Tumors - genetics ; Solitary fibrous tumour</subject><ispartof>Journal of clinical pathology, 2011-10, Vol.64 (10), p.866-869</ispartof><rights>2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright: 2011 (c) 2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b445t-ffadf0d6e2c7f77a1495cc4967756c0d84ad79181e753684d6df30d7a01c1be13</citedby><cites>FETCH-LOGICAL-b445t-ffadf0d6e2c7f77a1495cc4967756c0d84ad79181e753684d6df30d7a01c1be13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://jcp.bmj.com/content/64/10/866.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttps://jcp.bmj.com/content/64/10/866.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,776,780,3182,23551,27903,27904,77347,77378</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24560123$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21725042$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Walters, Matthew P</creatorcontrib><creatorcontrib>McPhail, Ellen D</creatorcontrib><creatorcontrib>Law, Mark E</creatorcontrib><creatorcontrib>Folpe, Andrew L</creatorcontrib><title>BCL-6 expression in mesenchymal tumours: an immunohistochemical and fluorescence in situ hybridisation study</title><title>Journal of clinical pathology</title><addtitle>J Clin Pathol</addtitle><description>The BCL-6 proto-oncogene encodes a transcriptional repressor protein. Among normal tissues, BCL-6 expression is confined to germinal center B-cells and a subpopulation of T-helper cells. Little is known about BCL-6 expression in mesenchymal tissues. We examined a series of solitary fibrous tumor (SFT) and other mesenchymal tumors for BCL-6 expression. Immunohistochemistry for BCL-6 was performed on 64 mesenchymal tumors [26 SFT (19 benign/uncertain, 7 malignant), 6 synovial sarcomas (SS), 5 gastrointestinal stromal tumors (GIST), 5 malignant peripheral nerve sheath tumors (MPNST), 5 leiomyosarcomas (LMS), 9 leiomyomas (LM) 4 desmoid tumors (DT), 4 perineuriomas (PN)]. Nuclear immunoreactivity was considered positive. Six BCL-6 positive SFT were also tested for BCL-6 gene rearrangement/amplification by FISH. Nuclear expression of BCL-6 was seen in 13/26 SFT, 5/5 LMS, 1/9 LM, 5/6 SS, 1/5 GIST, 1/5 MPNST, 1/4 PN, and 0/5 DT. BCL-6 expression was significantly more frequent in malignant (6/7) as compared with benign/uncertain SFT (6/19) (p=0.02) and in LMS (5/5) as compared with LM (1/9) (p=0.003). FISH for BCL-6 rearrangement/amplification was negative in all tested cases. We have observed BCL-6 expression in 50% or more of SFT, SS, and LMS, and in a lesser percentage of LM, GIST, MPNST and PN. Significantly more frequent expression of BCL-6 in malignant compared with benign/uncertain SFT and in LMS compared with LM suggests abnormalities in the BCL-6 signaling pathway may contribute to malignant transformation in at least some mesenchymal tumors. It is unlikely that BCL-6 expression in mesenchymal tumors is due to BCL-6 gene amplification or rearrangement. amplification or rearrangement.</description><subject>aeromonas</subject><subject>bcl-6</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Cell Transformation, Neoplastic - chemistry</subject><subject>Cell Transformation, Neoplastic - genetics</subject><subject>cytogenetics</subject><subject>DNA-Binding Proteins - analysis</subject><subject>DNA-Binding Proteins - genetics</subject><subject>Gene Amplification</subject><subject>Gene Rearrangement</subject><subject>haematopathology</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>immunophenotyping of leukaemias/lymphomas</subject><subject>in situ hybridisation</subject><subject>In Situ Hybridization, Fluorescence</subject><subject>Investigative techniques, diagnostic techniques (general aspects)</subject><subject>lymphoma</subject><subject>malt-lymphoma</subject><subject>Medical sciences</subject><subject>Mesoderm - chemistry</subject><subject>Mesoderm - pathology</subject><subject>Minnesota</subject><subject>molecular genetics</subject><subject>neoplasms</subject><subject>Neoplasms, Connective Tissue - chemistry</subject><subject>Neoplasms, Connective Tissue - genetics</subject><subject>Neoplasms, Connective Tissue - pathology</subject><subject>Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques</subject><subject>Proto-Oncogene Proteins c-bcl-6</subject><subject>sarcoma</subject><subject>Solitary Fibrous Tumors - chemistry</subject><subject>Solitary Fibrous Tumors - genetics</subject><subject>Solitary fibrous tumour</subject><issn>0021-9746</issn><issn>1472-4146</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqNkUtv1DAUhS1ERaeFnwCKhBCrUN_4lbCDEW2RRkXiubQcPxQPcTLYidT59_UowyCx6sZenO9cnXsPQi8BvwMg_Gqrez_s1NSVFQbID4aaPUEroKIqKVD-FK0wrqBsBOXn6CKlbUaIAPIMnVcgKoZptUL9x_Wm5IW930Wbkh-Hwg9FsMkOutsH1RfTHMY5pveFylII8zB2Pk2j7mzwOutqMIXr5zHbdTbZgz_5aS66fRu98UlNh6lpms3-OTpzqk_2xfG_RD-uP31f35abLzef1x82ZUspm0rnlHHYcFtp4YRQQBumNW24EIxrbGqqjGigBisY4TU13DiCjVAYNLQWyCV6u8zdxfHPbNMkg8_p-l4NdpyTrBtaA-eEZ_L1f-Q2bzvkcBJEDZgIDCJTbKF0HFOK1sld9EHFvQQsD23IUxvy0IZc2si-V8fpcxusObn-nj8Db46ASvmYLqpB-_SPo4xjqEjmyoXLp7f3J13F35ILIpi8-7mWnP76dn1z-1U2mccL34btI7M-AOqPtN4</recordid><startdate>20111001</startdate><enddate>20111001</enddate><creator>Walters, Matthew P</creator><creator>McPhail, Ellen D</creator><creator>Law, Mark E</creator><creator>Folpe, Andrew L</creator><general>BMJ Publishing Group Ltd and Association of Clinical Pathologists</general><general>BMJ Publishing Group</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20111001</creationdate><title>BCL-6 expression in mesenchymal tumours: an immunohistochemical and fluorescence in situ hybridisation study</title><author>Walters, Matthew P ; McPhail, Ellen D ; Law, Mark E ; Folpe, Andrew L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b445t-ffadf0d6e2c7f77a1495cc4967756c0d84ad79181e753684d6df30d7a01c1be13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>aeromonas</topic><topic>bcl-6</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Cell Transformation, Neoplastic - chemistry</topic><topic>Cell Transformation, Neoplastic - genetics</topic><topic>cytogenetics</topic><topic>DNA-Binding Proteins - analysis</topic><topic>DNA-Binding Proteins - genetics</topic><topic>Gene Amplification</topic><topic>Gene Rearrangement</topic><topic>haematopathology</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>immunophenotyping of leukaemias/lymphomas</topic><topic>in situ hybridisation</topic><topic>In Situ Hybridization, Fluorescence</topic><topic>Investigative techniques, diagnostic techniques (general aspects)</topic><topic>lymphoma</topic><topic>malt-lymphoma</topic><topic>Medical sciences</topic><topic>Mesoderm - chemistry</topic><topic>Mesoderm - pathology</topic><topic>Minnesota</topic><topic>molecular genetics</topic><topic>neoplasms</topic><topic>Neoplasms, Connective Tissue - chemistry</topic><topic>Neoplasms, Connective Tissue - genetics</topic><topic>Neoplasms, Connective Tissue - pathology</topic><topic>Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques</topic><topic>Proto-Oncogene Proteins c-bcl-6</topic><topic>sarcoma</topic><topic>Solitary Fibrous Tumors - chemistry</topic><topic>Solitary Fibrous Tumors - genetics</topic><topic>Solitary fibrous tumour</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Walters, Matthew P</creatorcontrib><creatorcontrib>McPhail, Ellen D</creatorcontrib><creatorcontrib>Law, Mark E</creatorcontrib><creatorcontrib>Folpe, Andrew L</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Walters, Matthew P</au><au>McPhail, Ellen D</au><au>Law, Mark E</au><au>Folpe, Andrew L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>BCL-6 expression in mesenchymal tumours: an immunohistochemical and fluorescence in situ hybridisation study</atitle><jtitle>Journal of clinical pathology</jtitle><addtitle>J Clin Pathol</addtitle><date>2011-10-01</date><risdate>2011</risdate><volume>64</volume><issue>10</issue><spage>866</spage><epage>869</epage><pages>866-869</pages><issn>0021-9746</issn><eissn>1472-4146</eissn><coden>JCPAAK</coden><abstract>The BCL-6 proto-oncogene encodes a transcriptional repressor protein. Among normal tissues, BCL-6 expression is confined to germinal center B-cells and a subpopulation of T-helper cells. Little is known about BCL-6 expression in mesenchymal tissues. We examined a series of solitary fibrous tumor (SFT) and other mesenchymal tumors for BCL-6 expression. Immunohistochemistry for BCL-6 was performed on 64 mesenchymal tumors [26 SFT (19 benign/uncertain, 7 malignant), 6 synovial sarcomas (SS), 5 gastrointestinal stromal tumors (GIST), 5 malignant peripheral nerve sheath tumors (MPNST), 5 leiomyosarcomas (LMS), 9 leiomyomas (LM) 4 desmoid tumors (DT), 4 perineuriomas (PN)]. Nuclear immunoreactivity was considered positive. Six BCL-6 positive SFT were also tested for BCL-6 gene rearrangement/amplification by FISH. Nuclear expression of BCL-6 was seen in 13/26 SFT, 5/5 LMS, 1/9 LM, 5/6 SS, 1/5 GIST, 1/5 MPNST, 1/4 PN, and 0/5 DT. BCL-6 expression was significantly more frequent in malignant (6/7) as compared with benign/uncertain SFT (6/19) (p=0.02) and in LMS (5/5) as compared with LM (1/9) (p=0.003). FISH for BCL-6 rearrangement/amplification was negative in all tested cases. We have observed BCL-6 expression in 50% or more of SFT, SS, and LMS, and in a lesser percentage of LM, GIST, MPNST and PN. Significantly more frequent expression of BCL-6 in malignant compared with benign/uncertain SFT and in LMS compared with LM suggests abnormalities in the BCL-6 signaling pathway may contribute to malignant transformation in at least some mesenchymal tumors. It is unlikely that BCL-6 expression in mesenchymal tumors is due to BCL-6 gene amplification or rearrangement. amplification or rearrangement.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd and Association of Clinical Pathologists</pub><pmid>21725042</pmid><doi>10.1136/jclinpath-2011-200185</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0021-9746 |
| ispartof | Journal of clinical pathology, 2011-10, Vol.64 (10), p.866-869 |
| issn | 0021-9746 1472-4146 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_894816636 |
| source | MEDLINE; BMJ Journals - NESLi2; PubMed Central |
| subjects | aeromonas bcl-6 Biological and medical sciences Biomarkers, Tumor - analysis Biomarkers, Tumor - genetics Cell Transformation, Neoplastic - chemistry Cell Transformation, Neoplastic - genetics cytogenetics DNA-Binding Proteins - analysis DNA-Binding Proteins - genetics Gene Amplification Gene Rearrangement haematopathology Humans Immunohistochemistry immunophenotyping of leukaemias/lymphomas in situ hybridisation In Situ Hybridization, Fluorescence Investigative techniques, diagnostic techniques (general aspects) lymphoma malt-lymphoma Medical sciences Mesoderm - chemistry Mesoderm - pathology Minnesota molecular genetics neoplasms Neoplasms, Connective Tissue - chemistry Neoplasms, Connective Tissue - genetics Neoplasms, Connective Tissue - pathology Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques Proto-Oncogene Proteins c-bcl-6 sarcoma Solitary Fibrous Tumors - chemistry Solitary Fibrous Tumors - genetics Solitary fibrous tumour |
| title | BCL-6 expression in mesenchymal tumours: an immunohistochemical and fluorescence in situ hybridisation study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T07%3A18%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=BCL-6%20expression%20in%20mesenchymal%20tumours:%20an%20immunohistochemical%20and%20fluorescence%20in%20situ%20hybridisation%20study&rft.jtitle=Journal%20of%20clinical%20pathology&rft.au=Walters,%20Matthew%20P&rft.date=2011-10-01&rft.volume=64&rft.issue=10&rft.spage=866&rft.epage=869&rft.pages=866-869&rft.issn=0021-9746&rft.eissn=1472-4146&rft.coden=JCPAAK&rft_id=info:doi/10.1136/jclinpath-2011-200185&rft_dat=%3Cproquest_cross%3E894816636%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1781037017&rft_id=info:pmid/21725042&rfr_iscdi=true |